Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025
Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer’s disease agitation with data expected in second half of 2025
Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025
Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026
Conference call today at 8:00am ET
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.